



For Immediate Release

February 3, 2026

Sumitomo Chemical Announces Revisions to Its Financial Forecast and Projected Dividend for the Full Year Ending March 31, 2026

Based on recent performance trends, Sumitomo Chemical (hereinafter, the "Company") has made revisions to its consolidated financial forecast for the full year ending March 31, 2026, previously announced on November 4, 2025, and the projected dividend, previously announced on May 14, 2025, as detailed below.

1. Revisions to Consolidated Financial Forecast for the Full Year Ending March 31, 2026 (April 1 2025-March 31, 2026)

(Millions of yen)

	Sales Revenue	Core Operating Income*	Operating Income	Net Income Attributable to Owners of the Parent	Earnings per Share (yen)
Previous forecast (A)	2,290,000	185,000	160,000	45,000	27.50
Revised forecast (B)	2,300,000	200,000	165,000	55,000	33.61
Variance in amount (B-A)	10,000	15,000	5,000	10,000	
Variance in percentage (%)	0.4%	8.1%	3.1%	22.2%	
Results for the full year ended March 31, 2025	2,606,281	140,519	193,033	38,591	23.59

* Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

Reasons for the Revision

Regarding the consolidated financial results for FY2025, shipments of semiconductor processing materials in the ICT & Mobility Solutions segment are forecasted to increase. The Company took into account uncertainty in the business environment and incorporated risks into its previous financial forecast, but the Company has made steady progress in its business activities. Due to this, the Company expects that sales revenue and core operating income will exceed its previous forecast.

Operating income and net income attributable to owners of the parent are also expected to exceed the previous forecast due to the increase in core operating income.

2. Revision to the Projected Dividend

	Dividend per share		
	Interim	Fiscal year-end	Annual
Previous forecast (Announced on May 14, 2025)		¥6.00	¥12.00
Revised forecast		¥7.50	¥13.50
Actual result	¥6.00		
Previous year results (Fiscal Year Ended March 31, 2025)	¥3.00	¥6.00	¥9.00

Reasons for the Revision

The Company places a high priority on shareholder return and makes it a policy to maintain stable dividend payments, while giving due consideration to its business performance and a dividend payout ratio for each fiscal year and the amount of retained earnings necessary for future growth. Because of the upward revisions as stated above, the Company decided to revise the projected year-end dividend to ¥7.5 per share. As a result, the Company's annual dividend will be ¥13.5 per share.

Cautionary Statement

Statements made in this document with respect to the Company's current plans, estimates, strategies and beliefs that are not historical facts are forward looking statements about the future performance of the Company. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties.

The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in the Company's markets; demand for, and competitive pricing pressure on, the Company's products in the marketplace; the Company's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

(Supplemental information)

Consolidated Financial Forecast by Segment for Full Year Ending March 31, 2026

(Millions of yen)

		Fiscal 2025 Previous Forecast (A)	Fiscal 2025 Revised Forecast (B)	Variance in Amount (B-A)	Results for the Full Year Ended March 31, 2025
Agro & Life Solutions	Sales revenue	530,000	530,000	-	540,221
	Core operating income	55,000	55,000	-	54,978
ICT & Mobility Solutions	Sales revenue	550,000	560,000	10,000	606,995
	Core operating income	53,000	55,000	2,000	70,555
Advanced Medical Solutions	Sales revenue	60,000	60,000	-	62,145
	Core operating income	4,000	4,000	-	3,966
Essential & Green Materials	Sales revenue	680,000	680,000	-	899,029
	Core operating income	13,000	13,000	-	(58,471)
Sumitomo Pharma	Sales revenue	420,000	420,000	-	398,001
	Core operating income	100,000	100,000	-	35,337
Others & Adjustments	Sales revenue	50,000	50,000	-	99,890
	Core operating income	(40,000)	(27,000)	13,000	34,154
Total	Sales revenue	2,290,000	2,300,000	10,000	2,606,281
	Core operating income	185,000	200,000	15,000	140,519